Menambah dosis dengan asumsi akan mendapatkan manfaat lebih cepat justru meningkatkan risiko efek samping
Millet R, Urig S, Jacob J, Amtmann E, Moulinoux JP, et al
(NYSE: PFE) announced that based on results from the ongoing pharmacokinetic study (NCT06153758), the company has selected its preferred once-daily modified release formulation for danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist
10.1016/j.jhep.2014.05.004 J
It reduces the surface tension between oil and water phases to help them stay mixed and stable in a formulation
We found that cells derived from the Brunner's glands of mice pretreated with semaglutide contained significantly more mucus compared with Brunner's glands from vehicle-treated mice